Literature DB >> 19300997

Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).

Akihiro Takano1, Balázs Gulyás, Andrea Varrone, Ralph Paul Maguire, Christer Halldin.   

Abstract

PURPOSE: In a previous PET study on norepinephrine transporter (NET) occupancy in the nonhuman primate brain, the relationship between NET occupancy and atomoxetine plasma concentration, and occupancies among different brain regions, were not demonstrated adequately. It may therefore be difficult to translate the results to the clinical situations. In the present study, the detailed change of NET occupancy was investigated among a wider range of doses in a more advanced manner.
METHODS: Two rhesus monkeys were examined using a high-resolution PET system with (S,S)-[(18)F]FMeNER-D(2) under baseline conditions and after steady-state infusion of different doses of atomoxetine (0.003 to 0.12 mg/kg per hour). NET occupancy of the thalamus, brainstem and anterior cingulate cortex was calculated using BP(ND) obtained with the simplified reference tissue model.
RESULTS: NET occupancy increased regionally and uniformly as the plasma concentration of atomoxetine increased. The estimated Kd value (the amount to occupy 50% of NET) in the thalamus was 16 ng/ml.
CONCLUSION: The results indicate that clinical doses of atomoxetine would occupy NET almost completely.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300997     DOI: 10.1007/s00259-009-1118-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

2.  Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.

Authors:  T Spencer; J Biederman; T Wilens; J Prince; M Hatch; J Jones; M Harding; S V Faraone; L Seidman
Journal:  Am J Psychiatry       Date:  1998-05       Impact factor: 18.112

3.  Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Authors:  Nicholas Seneca; Balázs Gulyás; Andrea Varrone; Magnus Schou; Anu Airaksinen; Johannes Tauscher; Francois Vandenhende; William Kielbasa; Lars Farde; Robert B Innis; Christer Halldin
Journal:  Psychopharmacology (Berl)       Date:  2006-08-04       Impact factor: 4.530

4.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors:  L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats.

Authors:  T Kubota; K Hirota; H Yoshida; S Takahashi; N Anzawa; H Ohkawa; T Kushikata; A Matsuki
Journal:  Psychopharmacology (Berl)       Date:  1999-10       Impact factor: 4.530

6.  Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Authors:  Frank P Bymaster; Jason S Katner; David L Nelson; Susan K Hemrick-Luecke; Penny G Threlkeld; John H Heiligenstein; S Michelle Morin; Donald R Gehlert; Kenneth W Perry
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

7.  Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.

Authors:  H Berzewski; M Van Moffaert; C A Gagiano
Journal:  Eur Neuropsychopharmacol       Date:  1997-04       Impact factor: 4.600

8.  Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs.

Authors:  Yu-Shin Ding; Kuo-Shyan Lin; Victor Garza; Pauline Carter; David Alexoff; Jean Logan; Colleen Shea; Youwen Xu; Payton King
Journal:  Synapse       Date:  2003-12-15       Impact factor: 2.562

9.  Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.

Authors:  Akihiro Takano; Tetsuya Suhara; Yoko Ikoma; Fumihiko Yasuno; Jun Maeda; Tetsuya Ichimiya; Yasuhiko Sudo; Makoto Inoue; Yoshiro Okubo
Journal:  Int J Neuropsychopharmacol       Date:  2004-03       Impact factor: 5.176

10.  PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain.

Authors:  Magnus Schou; Christer Halldin; Judit Sóvágó; Victor W Pike; Håkan Hall; Balázs Gulyás; P David Mozley; David Dobson; E Shchukin; Robert B Innis; Lars Farde
Journal:  Synapse       Date:  2004-08       Impact factor: 2.562

View more
  12 in total

1.  Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Authors:  Jean-Dominique Gallezot; David Weinzimmer; Nabeel Nabulsi; Shu-Fei Lin; Krista Fowles; Christine Sandiego; Timothy J McCarthy; R Paul Maguire; Richard E Carson; Yu-Shin Ding
Journal:  Neuroimage       Date:  2010-09-30       Impact factor: 6.556

2.  Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER.

Authors:  Akihiro Takano; Balázs Gulyás; Andrea Varrone; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

3.  Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study.

Authors:  George Bush; Jennifer Holmes; Lisa M Shin; Craig Surman; Nikos Makris; Eric Mick; Larry J Seidman; Joseph Biederman
Journal:  Psychiatry Res       Date:  2012-11-10       Impact factor: 3.222

4.  Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2.

Authors:  Mizuho Sekine; Ryosuke Arakawa; Hiroshi Ito; Masaki Okumura; Takeshi Sasaki; Hidehiko Takahashi; Harumasa Takano; Yoshiro Okubo; Christer Halldin; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

5.  NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo.

Authors:  Akihiro Takano; Sangram Nag; Balázs Gulyás; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

6.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

7.  Sensitivity of [(11)C]ORM-13070 to increased extracellular noradrenaline in the CNS - a PET study in human subjects.

Authors:  Jussi Lehto; Jarkko Johansson; Lauri Vuorilehto; Pauliina Luoto; Eveliina Arponen; Harry Scheinin; Juha Rouru; Mika Scheinin
Journal:  Psychopharmacology (Berl)       Date:  2015-04-29       Impact factor: 4.530

8.  Amphetamine decreases α2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain.

Authors:  Sjoerd J Finnema; Zoë A Hughes; Merja Haaparanta-Solin; Vladimir Stepanov; Ryuji Nakao; Katarina Varnäs; Andrea Varrone; Eveliina Arponen; Päivi Marjamäki; Katariina Pohjanoksa; Lauri Vuorilehto; Phebian A Babalola; Olof Solin; Sarah Grimwood; Jukka Sallinen; Lars Farde; Mika Scheinin; Christer Halldin
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-13       Impact factor: 5.176

9.  Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter.

Authors:  Catharina Neudorfer; Amir Seddik; Karem Shanab; Andreas Jurik; Christina Rami-Mark; Wolfgang Holzer; Gerhard Ecker; Markus Mitterhauser; Wolfgang Wadsak; Helmut Spreitzer
Journal:  Molecules       Date:  2015-01-20       Impact factor: 4.411

10.  Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.

Authors:  Patrick T Udvardi; Karl J Föhr; Carolin Henes; Stefan Liebau; Jens Dreyhaupt; Tobias M Boeckers; Andrea G Ludolph
Journal:  Drug Des Devel Ther       Date:  2013-12-04       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.